Deciphering riddles in molecular subtyping of bladder cancer DOI Creative Commons
Yuxiao Li, Shan Huang, W. Ju

и другие.

Asian journal of urology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Bladder cancer (BCa) is a prevalent malignant tumor in the urinary system. Molecular subtyping, utilizing molecular characteristics, represents novel classification system that has demonstrated its efficacy diagnosis and treatment. Given critical role of subtyping BCa treatment, acquiring comprehensive understanding imperative for guiding treatment decisions, optimizing risk assessment systems, ultimately improving patient prognosis. In this review, we provide overview research progress BCa, with primary focus on discussing utility various modalities including neoadjuvant chemotherapy, immunotherapy, targeted therapy. addition, review also covers trimodality antibody-drug conjugates, small cell BCa. We present responsiveness or resistance different subtypes to therapeutic modalities. The basal subtype demonstrates favorable sensitivity chemotherapy across multiple whereas luminal infiltrated exhibits potential susceptibility immunotherapy. terms therapy, basal-like basal/squamous some classifications have shown notable epidermal growth factor receptor-targeted Moreover, University Texas M.D. Anderson Cancer Center classification, papillary according Genome Atlas Research Network 2017, unstable type 2019 Subtyping show fibroblast receptor 3-targeted significance impact evaluating progression, predicting prognosis are increasingly acknowledged. Accurate broad application can bring good benefits clinical decision-making, assessment, prognostic evaluation.

Язык: Английский

Urinary Tract Cytopathology DOI
Mercè Jordà, Oleksandr N. Kryvenko,

Fiona Hanly

и другие.

Surgical pathology clinics, Год журнала: 2024, Номер 17(3), С. 383 - 394

Опубликована: Июль 14, 2024

Язык: Английский

Процитировано

2
The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer DOI Creative Commons
Tatiana Cano Barbadilla, Martina Álvarez, Juan Daniel Prieto Cuadra

и другие.

Diagnostics, Год журнала: 2024, Номер 14(22), С. 2501 - 2501

Опубликована: Ноя. 8, 2024

Bladder cancer (BC) is a highly heterogeneous disease, presenting clinical challenges, particularly in predicting patient outcomes and selecting effective treatments. Molecular subtyping has emerged as an essential tool for understanding the biological diversity of BC; however, its implementation practice remains limited due to high costs complexity genomic techniques. This review examines role immunohistochemistry (IHC) surrogate marker molecular BC, highlighting potential bridge gap between advanced classifications routine application; Methods: We explore evolution taxonomic classification with particular focus on cytokeratin (KRT) expression patterns normal urothelium, which are key identifying basal luminal subtypes. Furthermore, we emphasise need consensus IHC markers reliably define these subtypes, facilitating wider standardised use. The also analyses application both muscle-invasive (MIBC) non-muscle-invasive bladder (NMIBC), attention less extensively studied NMIBC cases. discuss practical advantages subtyping, including cost effectiveness feasibility standard pathology laboratories, alongside ongoing challenges such requirement protocols external validation across diverse settings; Conclusions: While limitations, it offers viable alternative laboratories lacking access Further research required determine optimal combination markers, establish diagnostic algorithm, validate through large-scale trials. will ultimately enhance accuracy, guide treatment decisions, improve outcomes.

Язык: Английский

Процитировано

1
Prognostic impact of EGFR expression and immunohistochemistry-based “molecular classification” in bladder cancer DOI

Yusuf Onder Ozsagir,

Elif Özsağır, Eyüp Dil

и другие.

Annals of Diagnostic Pathology, Год журнала: 2024, Номер 73, С. 152380 - 152380

Опубликована: Окт. 10, 2024

Язык: Английский

Процитировано

0
Deciphering riddles in molecular subtyping of bladder cancer DOI Creative Commons
Yuxiao Li, Shan Huang, W. Ju

и другие.

Asian journal of urology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Bladder cancer (BCa) is a prevalent malignant tumor in the urinary system. Molecular subtyping, utilizing molecular characteristics, represents novel classification system that has demonstrated its efficacy diagnosis and treatment. Given critical role of subtyping BCa treatment, acquiring comprehensive understanding imperative for guiding treatment decisions, optimizing risk assessment systems, ultimately improving patient prognosis. In this review, we provide overview research progress BCa, with primary focus on discussing utility various modalities including neoadjuvant chemotherapy, immunotherapy, targeted therapy. addition, review also covers trimodality antibody-drug conjugates, small cell BCa. We present responsiveness or resistance different subtypes to therapeutic modalities. The basal subtype demonstrates favorable sensitivity chemotherapy across multiple whereas luminal infiltrated exhibits potential susceptibility immunotherapy. terms therapy, basal-like basal/squamous some classifications have shown notable epidermal growth factor receptor-targeted Moreover, University Texas M.D. Anderson Cancer Center classification, papillary according Genome Atlas Research Network 2017, unstable type 2019 Subtyping show fibroblast receptor 3-targeted significance impact evaluating progression, predicting prognosis are increasingly acknowledged. Accurate broad application can bring good benefits clinical decision-making, assessment, prognostic evaluation.

Язык: Английский

Процитировано

0